AGN

Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals plans Phase 2 stroke and TBI study after successful DMT single dose study

Vancouver --News Direct-- Algernon Pharmaceuticals Inc.Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to provide an update on subsidiary Algernon NeuroScience successfully completing the highest planned single dose of its escalating Phase 1 clinical study of an intravenous formulation of AP-188 or DMT.... Read More...

Algernon Pharmaceuticals subsidiary Algernon NeuroScience doses first patient in stroke study

Vancouver, BC --News Direct-- Algernon Pharmaceuticals Inc.Algernon Pharmaceuticals CEO Christopher Moreau said the company has announced that its subsidiary Algernon NeuroScience has dosed the first subject in the Phase 1 DMT clinical stroke study. Moreau told Proactive this dosing was in the Netherlands where the study is being conducte... Read More...

Algernon Pharmaceuticals CEO To Deliver Virtual Keynote Presentation on Company’s DMT Program at the International Microdose DMT Conference

VANCOUVER, British Columbia, Sept. 09, 2021 -- Algernon Pharmaceuticals Inc.ย (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the โ€œCompanyโ€ or โ€œAlgernonโ€) a clinical stage pharmaceutical development company, is pleased to announce that its CEO Christopher J. Moreau will be delivering the Keynote Presentation at the Microdose Virtual 2021 โ€œThe ... Read More...

Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons by 40% in Preclinical Study at Sub Hallucinogenic Dose

VANCOUVER, British Columbia, Sept. 07, 2021 -- Algernon Pharmaceuticals Inc.ย (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the โ€œCompanyโ€ or โ€œAlgernonโ€) a clinical stage pharmaceutical development company, is pleased to announce that it has confirmed in its own preclinical study, that AP-188 (โ€œN,N-Dimethyltryptamine or โ€œDMTโ€), increased the ... Read More...